{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:31:44Z","timestamp":1790803904550,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["23NSFSC5020"],"award-info":[{"award-number":["23NSFSC5020"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jgar.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:28:52Z","timestamp":1683757732000},"page":"214-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Qi","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-8049","authenticated-orcid":false,"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.05.001_bib0001","unstructured":"World Health Organization. Global tuberculosis report 2021, https:\/\/www.who.int\/publications\/i\/item\/9789240037021; 2021 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/230240bc-bcf3-46b2-9b21-2e6e584f7333","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.jgar.2023.05.001_bib0003","first-page":"1701354.","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in","volume":"50","author":"Miotto","year":"2017","journal-title":"Mycobacterium tuberculosis. Eur Respir J"},{"key":"10.1016\/j.jgar.2023.05.001_bib0004","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment, https:\/\/www.who.int\/publications\/i\/item\/9789241550529; 2019 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0005","unstructured":"World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, https:\/\/www.who.int\/publications\/i\/item\/9789240018662; 2020 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0006","doi-asserted-by":"crossref","first-page":"870768","DOI":"10.3389\/fimmu.2022.870768","article-title":"Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review","volume":"13","author":"Yusoof","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgar.2023.05.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01164-21","article-title":"Role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex","volume":"65","author":"Vargas","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib0008","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.7717\/peerj.585","article-title":"Culture-independent detection and characterisation of Mycobacterium tuberculosis and M. africanum in sputum samples using shotgun metagenomics on a benchtop sequencer","volume":"2","author":"Doughty","year":"2014","journal-title":"PeerJ"},{"key":"10.1016\/j.jgar.2023.05.001_bib0009","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmi.2016.10.022","article-title":"Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives","volume":"23","author":"Sch\u00f6n","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2023.05.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01907-21","article-title":"Comparative performance of genomic methods for the detection of pyrazinamide resistance and heteroresistance in Mycobacterium tuberculosis","volume":"60","author":"Whitfield","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib0011","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.ijid.2021.03.033","article-title":"Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection","volume":"113","author":"Lam","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib0012","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/JCM.02268-10","article-title":"Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB\/RIF system","volume":"49","author":"Hillemann","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib0013","doi-asserted-by":"crossref","first-page":"575","DOI":"10.21037\/atm-22-1374","article-title":"GeneXpert MTB\/RIF combined with conventional methods for tuberculosis in Shanghai Regional Medical Center: a retrospective diagnostic study","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jgar.2023.05.001_bib0014","unstructured":"World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs, https:\/\/www.who.int\/publications\/i\/item\/9789241516136; 2016 (accessed july 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1128\/AAC.06272-11","article-title":"Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis","volume":"56","author":"Pantel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib0016","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5588\/ijtld.18.0562","article-title":"Evaluation of MTBDRsl for detecting resistance in Mycobacterium tuberculosis to second-line drugs","volume":"23","author":"Chandak","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib0017","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis, https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.5; 2018 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0018","unstructured":"World Health Organization. Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex, https:\/\/www.who.int\/publications\/i\/item\/9789240047419; 2022 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2023.05.001_bib0020","doi-asserted-by":"crossref","first-page":"2200239","DOI":"10.1183\/13993003.00239-2022","article-title":"CRyPTIC Consortium. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis","volume":"60","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2023.05.001_bib0021","doi-asserted-by":"crossref","first-page":"727220","DOI":"10.3389\/fimmu.2022.727220","article-title":"Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgar.2023.05.001_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13073-020-00793-8","article-title":"tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era","volume":"12","author":"Beckert","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.jgar.2023.05.001_bib48","doi-asserted-by":"crossref","first-page":"106385","DOI":"10.1016\/j.ijantimicag.2021.106385","article-title":"Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance","volume":"58","author":"Chaiyachat","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.05.001_bib49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/AAC.48.2.596-601.2004","article-title":"Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates","volume":"48","author":"Cheng","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib50","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1128\/AAC.01049-15","article-title":"Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates","volume":"60","author":"Chien","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijantimicag.2017.04.010","article-title":"High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan","volume":"50","author":"Chien","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.05.001_bib52","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1128\/AAC.00539-16","article-title":"Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates","volume":"60","author":"Disratthakit","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib53","first-page":"223","article-title":"Moxifloxacin resistance in the F15\/LAM4\/KZN extensively drug-resistant strain of","volume":"7","author":"Dookie","year":"2014","journal-title":"Mycobacterium tuberculosis. Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.001_bib0040","doi-asserted-by":"crossref","first-page":"655653","DOI":"10.3389\/fmicb.2021.655653","article-title":"Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination","volume":"12","author":"Du","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib55","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JCM.00231-11","article-title":"Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas","volume":"49","author":"El Sahly","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib56","doi-asserted-by":"crossref","first-page":"e02518","DOI":"10.1128\/AAC.02530-18","article-title":"High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness","volume":"63","author":"Ghajavand","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib57","doi-asserted-by":"crossref","first-page":"e00915","DOI":"10.1128\/AAC.00915-19","article-title":"Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan","volume":"63","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijid.2020.01.021","article-title":"Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene","volume":"92","author":"Huo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib59","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.5588\/ijtld.12.0949","article-title":"Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs","volume":"17","author":"Imperiale","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41598-020-57992-x","article-title":"Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing","volume":"10","author":"Ismail","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2023.05.001_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","article-title":"Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay","volume":"95","author":"Kambli","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jgar.2023.05.001_bib62","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1007\/s00203-021-02387-3","volume":"203","author":"Kardan-Yamchi","year":"2021","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib63","doi-asserted-by":"crossref","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","article-title":"Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China","volume":"73","author":"Liu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tube.2018.04.007","article-title":"Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia","volume":"111","author":"Martinez","year":"2018","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.001_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/ijmr.IJMR_1168_19","article-title":"Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai, India","volume":"154","author":"Nambiar","year":"2021","journal-title":"Indian Journal of Medical Research"},{"key":"10.1016\/j.jgar.2023.05.001_bib66","doi-asserted-by":"crossref","first-page":"1902383","DOI":"10.1183\/13993003.02383-2019","article-title":"Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients","volume":"55","author":"Nimmo","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2023.05.001_bib67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkv353","article-title":"Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB","volume":"71","author":"Niward","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244829","article-title":"Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M\/XDR-TB","volume":"15","author":"Nonghanphithak","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2023.05.001_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-17","article-title":"In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib70","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jinf.2020.01.007","article-title":"Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates","volume":"80","author":"Peretokina","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2023.05.001_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijid.2021.04.036","article-title":"Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against","volume":"106","author":"Qiao","year":"2021","journal-title":"Mycobacterium tuberculosis. Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12866-022-02475-4","article-title":"Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ na\u00efve TB patients in Pakistan","volume":"22","author":"Saeed","year":"2022","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib73","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dks033","article-title":"gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis","volume":"67","author":"Sirgel","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/pathogens10111422","article-title":"Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh","volume":"10","author":"Uddin","year":"2021","journal-title":"Pathogens"},{"issue":"10","key":"10.1016\/j.jgar.2023.05.001_bib75","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/antibiotics10101243","article-title":"Genetic profile of linezolid-resistant m. Tuberculosis clinical strains from moscow","volume":"10","author":"Ushtanit","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2023.05.001_bib76","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1128\/AAC.00287-09","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB","volume":"53","author":"Von Groll","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","article-title":"Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey","volume":"82","author":"Wang","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2023.05.001_bib78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tube.2014.03.005","article-title":"Prediction of XDR\/pre-XDR tuberculosis by genetic mutations among MDR cases from a hospital in Shandong, China","volume":"94","author":"Wang","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.jgar.2023.05.001_bib79","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jac\/dkm061","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure","volume":"59","author":"Wang","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib80","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/jac\/dkz206","article-title":"Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa","volume":"74","author":"Wasserman","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib81","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1128\/AAC.00662-15","article-title":"Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in","volume":"59","author":"Willby","year":"2015","journal-title":"Mycobacterium tuberculosis. Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib82","doi-asserted-by":"crossref","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","article-title":"Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan","volume":"12","author":"Wu","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2023.05.001_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00409-21","article-title":"Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013","volume":"9","author":"Xia","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2023.05.001_bib84","doi-asserted-by":"crossref","first-page":"e00239","DOI":"10.1128\/AAC.00239-17","article-title":"Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis","volume":"61","author":"Xu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijid.2020.07.044","article-title":"Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China","volume":"99","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","article-title":"Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea","volume":"38","author":"Yang","year":"2018","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jgar.2023.05.001_bib0042","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13756-021-00995-8","article-title":"Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition","volume":"10","author":"Yao","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2023.05.001_bib88","first-page":"280","article-title":"Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in Mycobacterium tuberculosis from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis","volume":"28","author":"Zhang","year":"2022","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.001_bib89","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","article-title":"Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China","volume":"43","author":"Zhang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.001_bib91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12879-021-06024-8","article-title":"Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.jgar.2023.05.001_bib92","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/jac\/dkx094","article-title":"Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region","volume":"72","author":"Zimenkov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib93","doi-asserted-by":"crossref","first-page":"e00165","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","article-title":"Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay","volume":"95","author":"Kambli","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.jgar.2023.05.001_bib0023","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/jac\/dkv499","article-title":"Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis","volume":"71","author":"Coeck","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib0024","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1073\/pnas.1525047113","article-title":"Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis","volume":"113","author":"Blower","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2023.05.001_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jgar.2017.10.003","article-title":"Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco","volume":"12","author":"Chaoui","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.05.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039754","article-title":"New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations","volume":"7","author":"Malik","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2023.05.001_bib0027","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.01550-10","article-title":"Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis","volume":"55","author":"Campbell","year":"2011","journal-title":"Antimicrob Agents Chemo."},{"key":"10.1016\/j.jgar.2023.05.001_bib0028","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.21037\/jtd.2019.11.03","article-title":"Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China","volume":"11","author":"Hameed","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib0029","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, https:\/\/www.who.int\/publications\/i\/item\/9789240028173; 2021 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0030","unstructured":"World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide, https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.19; 2018 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0031","unstructured":"World Health Organization. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians, https:\/\/www.who.int\/publications\/i\/item\/9789240046665; 2022 (accessed July 5, 2022)."},{"key":"10.1016\/j.jgar.2023.05.001_bib0032","first-page":"223","article-title":"A diarylquinoline drug active on the ATP synthase of","volume":"307","author":"Andries","year":"2005","journal-title":"Mtb. Tb. Sci."},{"key":"10.1016\/j.jgar.2023.05.001_bib0033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/antibiotics9030133","article-title":"Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid","volume":"9","author":"Nieto Ramirez","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2023.05.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500106","article-title":"Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline","volume":"1","author":"Preiss","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.jgar.2023.05.001_bib0035","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","article-title":"Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis","volume":"2","author":"Ismail","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jgar.2023.05.001_bib0036","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.001_bib0037","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.001_bib0038","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/IDR.S257145","article-title":"Genetic and virulence characteristics of linezolid and pretomanid dual drug-resistant strains induced from Mycobacterium tuberculosis in vitro","volume":"13","author":"Hu","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.001_bib0039","doi-asserted-by":"crossref","first-page":"100471","DOI":"10.1016\/j.epidem.2021.100471","article-title":"Quantifying transmission fitness costs of multi-drug resistant tuberculosis","volume":"36","author":"Pe\u010derska","year":"2021","journal-title":"Epidemics"},{"key":"10.1016\/j.jgar.2023.05.001_bib0041","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/antibiotics10101243","article-title":"Genetic profile of linezolid-resistant M. tuberculosis clinical strains from Moscow","volume":"10","author":"Ushtanit","year":"2021","journal-title":"Antibiotics"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:41Z","timestamp":1761991301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":87,"alternative-id":["S2213716523000759"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}